Ronquest NA, Paret K, Gould I, Barnett CL, Mladsi (she/her) DM. The evolution of ICER's review process for new medical interventions and a critical review of economic evaluations (2018-2019): how stakeholders can collaborate with ICER to improve the quality of evidence in ICER's reports. J Manag Care Spec Pharm. 2021 Nov;27(11):1601-12. doi: 10.18553/jmcp.2021.27.11.1601
Nazareth T, Purser M, Bhaila R, Philbin M, Mladsi D. The economic burden of moderate-to-severe multiple sclerosis relapse in the United States: findings from a systematic literature review. Poster presented at the 69th AAN Annual Meeting; April 2017. Boston, MA. [abstract] Neurology. 2017 Apr 18; 88(16 Suppl).
Lehmann K, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Duragesic) with controlled release morphine. Eur J Health Econ. 2002;3:111-9. doi: 10.1007/s10198-002-0097-6.
Neighbors DM, Bell TJ, Wilson J, Dodd SL. Economic evaluation of the fentanyl transdermal system for the treatment of chronic moderate to severe pain. J Pain Symptom Manage. 2001 Feb 1;21(2):129-43. doi: 10.1016/s0885-3924(00)00247-5.
Neighbors DM, Dodd SL. Re: economic evaluation of fentanyl - Response. J Pain Symptom Manage. 2001 Jan 1;22(1):541-3.